RESUMEN
A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.
Asunto(s)
Antibacterianos/farmacología , Complejo Respiratorio Bovino/patología , Enfermedades de los Bovinos/patología , Disacáridos/farmacología , Compuestos Heterocíclicos/farmacología , Mannheimia haemolytica/efectos de los fármacos , Pasteurella multocida/efectos de los fármacos , Animales , Antibacterianos/uso terapéutico , Complejo Respiratorio Bovino/tratamiento farmacológico , Complejo Respiratorio Bovino/microbiología , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Enfermedades de los Bovinos/microbiología , Estudios Transversales , ADN Viral/genética , ADN Viral/metabolismo , Virus de la Diarrea Viral Bovina/efectos de los fármacos , Virus de la Diarrea Viral Bovina/genética , Virus de la Diarrea Viral Bovina/aislamiento & purificación , Disacáridos/uso terapéutico , Herpesvirus Bovino 1/efectos de los fármacos , Herpesvirus Bovino 1/genética , Herpesvirus Bovino 1/aislamiento & purificación , Compuestos Heterocíclicos/uso terapéutico , Mannheimia haemolytica/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Nasofaringe/microbiología , Nasofaringe/virología , Pasteurella multocida/aislamiento & purificación , Reacción en Cadena de la Polimerasa , Estudios Prospectivos , ARN Viral/genética , ARN Viral/metabolismo , Virus Sincitial Respiratorio Bovino/efectos de los fármacos , Virus Sincitial Respiratorio Bovino/genética , Virus Sincitial Respiratorio Bovino/aislamiento & purificación , Factores de Riesgo , Insuficiencia del TratamientoRESUMEN
An anti-mannheimiosis agent, aldsulfin, was isolated from a culture broth of the fungus Lasiodiplodia pseudotheobromae FKI-4499, together with a known compound, lasiodipline C, using bioassay-guided fractionation. Spectroscopic analysis of aldsulfin, using NMR, mass spectrometry, and CD analyses revealed it to be an epithiodiketopiperazine with an unstable and unusual hemithioaminal moiety. Aldsulfin showed antibacterial activity against Mannheimia haemolytica and Pasteurella multocida.
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacología , Ascomicetos/metabolismo , Mannheimia haemolytica/efectos de los fármacos , Antibacterianos/aislamiento & purificación , Antibacterianos/metabolismo , Ascomicetos/clasificación , Ascomicetos/genética , Medios de Cultivo/química , Dicetopiperazinas/química , Dicetopiperazinas/farmacología , Evaluación Preclínica de Medicamentos , Fermentación , Espectroscopía de Resonancia Magnética , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Pasteurella multocida/efectos de los fármacosRESUMEN
Pasteurellosis is one of the rabbit's most bacterial severe diseases and leads to considerable financial damages in large production systems worldwide. Antibiotic use in animals may lead to antibiotic residues in animal products, including meat. Therefore, this study was designed to evaluate the potential role of grape seed extract (GSE) in treating Pasteurella multocida infection in rabbits. For this purpose, 45 weaned male New Zealand rabbits were divided into three groups; control, infected and infected-GSE treated. Experimental P. multocida infection in rabbits induced a remarkable decrease in body weight, body weight gain, as well as microcytic hypochromic anaemia, leucocytosis, neutrophilia and lymphocytopenia. Also, a significant increase in the hepatic and renal injury biomarkers, in interleukin-6, total globulin, α, ß and γ globulins, as well as a marked reduction in total protein and albumin, were recorded in the P. multocida-infected rabbits. Treatment of infected rabbits with GSE modulated most of these altered parameters. This study endorses the administration of GSE for the treatment of Pasteurellosis in rabbits. Further studies are required to identify the possible additional effects, appropriate doses and duration of the GSE therapy in rabbits Pasteurellosis.
Asunto(s)
Antibacterianos/farmacología , Extracto de Semillas de Uva/farmacología , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/efectos de los fármacos , Vitis/química , Animales , Masculino , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/microbiología , ConejosRESUMEN
Although 90% of BRD relapses are reported to receive retreatment with a different class of antimicrobial, studies examining the impact of antimicrobial selection (i.e. bactericidal or bacteriostatic) on retreatment outcomes and the emergence of antimicrobial resistance (AMR) are deficient in the published literature. This survey was conducted to determine the association between antimicrobial class selection for treatment and retreatment of BRD relapses on antimicrobial susceptibility of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Pathogens were isolated from samples submitted to the Iowa State University Veterinary Diagnostic Laboratory from January 2013 to December 2015. A total of 781 isolates with corresponding animal case histories, including treatment protocols, were included in the analysis. Original susceptibility testing of these isolates for ceftiofur, danofloxacin, enrofloxacin, florfenicol, oxytetracycline, spectinomycin, tilmicosin, and tulathromycin was performed using Clinical and Laboratory Standards Institute guidelines. Data were analyzed using a Bayesian approach to evaluate whether retreatment with antimicrobials of different mechanistic classes (bactericidal or bacteriostatic) increased the probability of resistant BRD pathogen isolation in calves. The posterior distribution we calculated suggests that an increased number of treatments is associated with a greater probability of isolates resistant to at least one antimicrobial. Furthermore, the frequency of resistant BRD bacterial isolates was greater with retreatment using antimicrobials of different mechanistic classes than retreatment with the same class. Specifically, treatment protocols using a bacteriostatic drug first followed by retreatment with a bactericidal drug were associated with a higher frequency of resistant BRD pathogen isolation. In particular, first treatment with tulathromycin (bacteriostatic) followed by ceftiofur (bactericidal) was associated with the highest probability of resistant M. haemolytica among all antimicrobial combinations. These observations suggest that consideration should be given to antimicrobial pharmacodynamics when selecting drugs for retreatment of BRD. However, prospective studies are needed to determine the clinical relevance to antimicrobial stewardship programs in livestock production systems.
Asunto(s)
Complejo Respiratorio Bovino/tratamiento farmacológico , Complejo Respiratorio Bovino/microbiología , Farmacorresistencia Microbiana/fisiología , Animales , Antibacterianos/farmacología , Antiinfecciosos/farmacología , Bovinos , Cefalosporinas , Disacáridos , Fluoroquinolonas , Compuestos Heterocíclicos , Mannheimia haemolytica/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Pasteurella multocida/efectos de los fármacos , Pasteurellaceae/efectos de los fármacos , Estudios Prospectivos , Recurrencia , Enfermedades Respiratorias/tratamiento farmacológico , Serogrupo , Tilosina/análogos & derivadosRESUMEN
Bacterial respiratory infections affecting pigs such as pneumonia, pleuropneumonia, and pleurisy, are a major health concern in the swine industry and are associated with important economic losses. This study aimed to investigate the antibacterial activities of essential oils against major swine respiratory pathogens with a view to developing a potential alternative to antibiotics. Their synergistic interactions with the bacteriocin nisin was also examined. Lastly, we assessed the in vitro biocompatibility of the most efficient essential oils using a pig tracheal epithelial cell line. Of the nine essential oils tested, those from cinnamon, thyme, and winter savory were the most active against Streptococcus suis, Actinobacillus pleuropneumoniae, Actinobacillus suis, Bordetella bronchiseptica, Haemophilus parasuis, and Pasteurella multocida, with minimum inhibitory concentrations and minimum bactericidal concentrations ranging from 0.01 to 0.156% (v/v). The main component found in cinnamon, thyme, and winter savory oils were cinnamaldehyde, thymol, and carvacrol, respectively. Treating pre-formed S. suis and A. pleuropneumoniae biofilms with thyme or winter savory oils significantly decreased biofilm viability. We also observed a synergistic growth inhibition of S. suis with mixtures of nisin and essential oils from thyme and winter savory. Concentrations of nisin and cinnamon, thyme and winter savory essential oils that were effective against bacterial pathogens had no effect on the viability of pig tracheal epithelial cells. The present study brought evidence that essential oils are potential antimicrobial agents against bacteria associated with porcine respiratory infections.
Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Infecciones Bacterianas/veterinaria , Aceites Volátiles/farmacología , Aceites de Plantas/farmacología , Enfermedades Respiratorias/veterinaria , Enfermedades de los Porcinos/microbiología , Animales , Antibacterianos/química , Infecciones Bacterianas/microbiología , Fenómenos Fisiológicos Bacterianos , Biopelículas/efectos de los fármacos , Cinnamomum zeylanicum/química , Cimenos , Pruebas de Sensibilidad Microbiana , Monoterpenos/farmacología , Nisina/farmacología , Aceites Volátiles/química , Pasteurella multocida/efectos de los fármacos , Pasteurella multocida/fisiología , Aceites de Plantas/química , Enfermedades Respiratorias/microbiología , Satureja/química , Streptococcus suis/efectos de los fármacos , Streptococcus suis/fisiología , Porcinos , Thymus (Planta)/químicaRESUMEN
Due to the emergence of virulent and antibiotic-resistant microbes, natural antimicrobials from herbal origins have been given more attention as an alternative therapy. This study provides an in vitro research framework to investigate the antibacterial activities of 5 herbal (marjoram, garlic, onion, cinnamon and black seed) oil extracts against 16 multidrug-resistant (MDR) and virulent P. multocida serogroup A isolates recovered from dead and clinically diseased rabbits. Pathogenicity of the screened isolates was further proven experimentally and was verified by PCR analyses of 5 randomly selected virulence genes encoding attachment and colonization proteins (ptfA, pfhA, and omp87), sialidases (nanB) and dermonecrotoxin (toxA). A total of 12 P. multocida isolates were highly pathogenic with the possession of all examined virulence genes, while the other 4 isolates were of lower pathogenicity with expression of the target genes except toxA. In vitro anti-P. multocida activities of the 5 extracts and their synergism rates with 4 antibiotic drugs revealed that marjoram and cinnamon extracts had the highest antibacterial activities and the highest synergism rates against the screened isolates. Pasteurella multocida virulence gene expression profiles were assessed via real-time quantitative reverse transcription PCR (qRT-PCR) in response to marjoram extract. The quantitative analyses showed less than five-fold reduction in the targeted virulence genes expression in presence of marjoram extract compared with the control. The findings from this study document a novel molecular inhibitory activity of marjoram against P. multocida multiple virulence genes and provide a proof of concept for its implementation as an alternative candidate for the treatment of pasteurellosis in farm animals in future.
Asunto(s)
Antiinfecciosos/farmacología , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Pasteurella multocida/efectos de los fármacos , Pasteurella multocida/fisiología , Extractos Vegetales/farmacología , Tracheophyta/química , Enfermedades de los Animales/tratamiento farmacológico , Enfermedades de los Animales/microbiología , Animales , Antiinfecciosos/química , Adhesión Bacteriana/efectos de los fármacos , Adhesión Bacteriana/genética , Toxinas Bacterianas/genética , Relación Dosis-Respuesta a Droga , Pruebas de Sensibilidad Microbiana , Infecciones por Pasteurella/veterinaria , Extractos Vegetales/químicaRESUMEN
PURPOSE: Pasteurella multocida (P. multocida) is a principal pathogen of domestic animals and an opportunistic pathogen of humans. It is the causative agent of pneumonia and haemorrhagic septicaemia in cattle, sheep and goats, fowl cholera in chickens and progressive atrophic rhinitis in swine. In this study, we investigated the humoral and cellular immune responses and protective immunity conferred by an iron-inactivated vaccine with bacterial DNA (IIV+bDNA) as an adjuvant in mice. METHODOLOGY: P. multocida was grown in BHI broth, inactivated with formalin and FeCl3 and adjuvanted with alum and bDNA. Mice were immunized with two whole-cell inactivated vaccine doses 2 weeks apart. The animals were challenged 4 weeks after booster immunization. Immunogens (vaccines and bDNA) posed no safety problems when mice were injected subcutaneously (s/c) with these preparations. The serum antibody titres were tested by ELISA. At 28 days post immunization, cell-mediated immunity responses were determined. The responses were measured by assay of IL-6 and IL-12 in lymphocyte spleen culture supernatants. RESULTS: ELISA results showed that the levels of antibodies in iron inactivated with bDNA adjuvant groups were higher than in the formalin inactivated with alum adjuvant vaccine group. The protection rate of IIV+bDNA adjuvant vaccine was superior to that of the other vaccines and it protected 100â% of the challenge group mice. Following immunization, bDNA promoted increased production of interleukins compared to the control groups. CONCLUSION: These studies indicate that bDNA is effective as an immune adjuvant, and along with stimulatory bDNA represent promising new humoral and cellular immune enhancers for vaccination applications. In addition, this vaccine is able to provide long-term protection against infection.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Vacunas Bacterianas/inmunología , ADN Bacteriano/inmunología , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/inmunología , Enfermedades de las Ovejas/prevención & control , Animales , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Vacunas Bacterianas/administración & dosificación , Cloruros/farmacología , ADN Bacteriano/administración & dosificación , Femenino , Compuestos Férricos/farmacología , Humanos , Inmunización , Interleucina-12/inmunología , Interleucina-6/inmunología , Ratones , Ratones Endogámicos BALB C , Infecciones por Pasteurella/inmunología , Infecciones por Pasteurella/prevención & control , Pasteurella multocida/efectos de los fármacos , Pasteurella multocida/genética , Ovinos , Enfermedades de las Ovejas/inmunología , Enfermedades de las Ovejas/microbiología , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/inmunologíaRESUMEN
Bovine respiratory disease is the most costly disease facing the cattle industry. Increasing resistance to antimicrobial treatment has been presented as a significant contributing factor, often through summarized susceptibility testing data. We assessed the relationship between previous antimicrobial treatment and antimicrobial susceptibility results from isolates of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni cultured from bovine respiratory cases submitted to the Iowa State University Veterinary Diagnostic Laboratory from 2013 to 2015. Antimicrobial susceptibility data from 1,251 bacterial isolates were included for analysis. More bacterial isolates from cattle that received antimicrobial treatment showed resistance compared to isolates from untreated cattle, and the percentage of resistant isolates increased as the number of antimicrobial treatments increased. Resistance to enrofloxacin, spectinomycin, tilmicosin, and tulathromycin was present in >75% of M. haemolytica isolates from cattle that had received 3 or more antimicrobial treatments; resistance to each of those 4 antimicrobials was present in ≤10% of M. haemolytica isolates from untreated cattle. Similar but less dramatic trends were apparent for isolates of P. multocida and H. somni. The percentage of multi-drug resistant bacterial isolates also increased with the number of treatments. Results of our study suggest that previous antimicrobial treatment may have a profound effect on antimicrobial susceptibility testing. Summarized susceptibility results from diagnostic laboratories should not be used to make generalized statements regarding trends in antimicrobial resistance without providing context regarding antimicrobial treatment history.
Asunto(s)
Antibacterianos/farmacología , Enfermedades de los Bovinos/microbiología , Mannheimia haemolytica/efectos de los fármacos , Pasteurella multocida/efectos de los fármacos , Pasteurellaceae/efectos de los fármacos , Enfermedades Respiratorias/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Enfermedades de los Bovinos/epidemiología , Farmacorresistencia Bacteriana , Iowa/epidemiología , Pruebas de Sensibilidad Microbiana , Infecciones por Pasteurellaceae/tratamiento farmacológico , Infecciones por Pasteurellaceae/epidemiología , Infecciones por Pasteurellaceae/microbiología , Infecciones por Pasteurellaceae/veterinaria , Enfermedades Respiratorias/epidemiología , Enfermedades Respiratorias/microbiología , Serogrupo , UniversidadesRESUMEN
Twenty-three isolates of Pasteurella multocida were tested for susceptibility to six aminoglycoside agents and screened by polymerase chain reaction for the presence of aminoglycoside resistance genes. In addition, mutations in the resistance-determining region of strains showing a high level of induced resistance to spectinomycin strains were examined. Susceptibility testing showed that all of the isolates were resistant to at least two types of aminoglycosides, and that the most effective antimicrobial was spectinomycin. The resistance genes aphA1, strB and aacA4 were present in all 23 isolates. In the three induced spectinomycin-resistant strains, a 9-bp deletion in rpsE that encodes ribosomal protein S5 was detected.
Asunto(s)
Aminoglicósidos/uso terapéutico , Antibacterianos/uso terapéutico , Enfermedades de los Bovinos/tratamiento farmacológico , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/efectos de los fármacos , Infecciones del Sistema Respiratorio/veterinaria , Proteínas Ribosómicas/genética , Espectinomicina/uso terapéutico , Animales , Bovinos , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/microbiología , China/epidemiología , Farmacorresistencia Bacteriana/genética , Pruebas de Sensibilidad Microbiana/veterinaria , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/epidemiología , Infecciones por Pasteurella/microbiología , Pasteurella multocida/genética , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/microbiologíaRESUMEN
The objectives of this study were to develop a new assay for the evaluation of the antimicrobial activities of essential oils (EOs) in vapour phase and to demonstrate the antimicrobial activities of commercial EOs against BRPs. To achieve the first objective, a microtube cap containing 100 µl of EO was embedded in an agar plate. An agar plug (diameter 13 mm) inoculated with a bacterial suspension containing108 CFU per ml was then placed over the cap and incubated at 37°C for 24 h. Subsequently, bacteria were recovered from the agar plug by immersion in 5 ml of broth for 10 min, followed by vortexing for 30 s, and the broths were then plated for enumeration. To demonstrate the usefulness of the assay, nine commercial EOs derived from the following specific plants: ajowan, carrot seed, cinnamon leaf, citronella, fennel, ginger grass, lavender, rosemary and thyme were first evaluated for their vapour phase antimicrobial activities against Mannheimia haemolytica serotype 1. Selected EOs were further tested against Pasteurella multocida and Histophilus somni. The EOs of ajowan, thyme and cinnamon leaf completely or partially inhibited BRPs growth. This new assay provided reproducible results on the vapour phase antimicrobial activities of EOs against BRPs. These results support further study of EOs as a potential mitigation strategy against BRPs. SIGNIFICANCE AND IMPACT OF THE STUDY: In this study, we present a new vapour phase assay for evaluating the antimicrobial activities of essential oils (EO) against bovine respiratory pathogens (BRPs). Using this assay, we identified EOs, such as ajowan, thyme and cinnamon leaf, that can effectively inhibit growth of the BRPs Mannheimia haemolytica serotype 1, Pasteurella multocida and Histophilus somni. This is the first study to demonstrate the vapour phase antimicrobial activity of EOs against BRPs.
Asunto(s)
Antibacterianos/farmacología , Enfermedades de los Bovinos/tratamiento farmacológico , Mannheimia haemolytica/crecimiento & desarrollo , Aceites Volátiles/farmacología , Pasteurella multocida/crecimiento & desarrollo , Aceites de Plantas/farmacología , Animales , Carum/química , Bovinos , Enfermedades de los Bovinos/microbiología , Cinnamomum zeylanicum/química , Mannheimia haemolytica/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/métodos , Pasteurella multocida/efectos de los fármacos , Thymus (Planta)/químicaRESUMEN
BACKGROUND: The most widely used measure of potency of antimicrobial drugs is Minimum Inhibitory Concentration (MIC). MIC is usually determined under standardised conditions in broths formulated to optimise bacterial growth on a species-by-species basis. This ensures comparability of data between laboratories. However, differences in values of MIC may arise between broths of differing chemical composition and for some drug classes major differences occur between broths and biological fluids such as serum and inflammatory exudate. Such differences must be taken into account, when breakpoint PK/PD indices are derived and used to predict dosages for clinical use. There is therefore interest in comparing MIC values in several broths and, in particular, in comparing broth values with those generated in serum. For the pig pneumonia pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida, MICs were determined for three drugs, florfenicol, oxytetracycline and marbofloxacin, in five broths [Mueller Hinton Broth (MHB), cation-adjusted Mueller Hinton Broth (CAMHB), Columbia Broth supplemented with NAD (CB), Brain Heart Infusion Broth (BHI) and Tryptic Soy Broth (TSB)] and in pig serum. RESULTS: For each drug, similar MIC values were obtained in all broths, with one exception, marbofloxacin having similar MICs for three broths and 4-5-fold higher MICs for two broths. In contrast, for both organisms, quantitative differences between broth and pig serum MICs were obtained after correction of MICs for drug binding to serum protein (fu serum MIC). Potency was greater (fu serum MIC lower) in serum than in broths for marbofloxacin and florfenicol for both organisms. For oxytetracycline fu serum:broth MIC ratios were 6.30:1 (P. multocida) and 0.35:1 (A. pleuropneumoniae), so that potency of this drug was reduced for the former species and increased for the latter species. The chemical composition of pig serum and broths was compared; major matrix differences in 14 constituents did not account for MIC differences. Bacterial growth rates were compared in broths and pig serum in the absence of drugs; it was concluded that broth/serum MIC differences might be due to differing growth rates in some but not all instances. CONCLUSIONS: For all organisms and all drugs investigated in this study, it is suggested that broth MICs should be adjusted by an appropriate scaling factor when used to determine pharmacokinetic/pharmacodynamic breakpoints for dosage prediction.
Asunto(s)
Actinobacillus pleuropneumoniae/efectos de los fármacos , Antibacterianos/farmacología , Pasteurella multocida/efectos de los fármacos , Neumonía Bacteriana/veterinaria , Enfermedades de los Porcinos/tratamiento farmacológico , Infecciones por Actinobacillus/tratamiento farmacológico , Infecciones por Actinobacillus/veterinaria , Animales , Fluoroquinolonas/farmacología , Pruebas de Sensibilidad Microbiana , Oxitetraciclina/farmacología , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/veterinaria , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Porcinos , Enfermedades de los Porcinos/microbiología , Tianfenicol/análogos & derivados , Tianfenicol/farmacologíaRESUMEN
The antimicrobial properties of amoxicillin were determined for the bovine respiratory tract pathogens, Mannheima haemolytica and Pasteurella multocida. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill curves were established. Pharmacokinetic (PK)/pharmacodynamic (PD) modelling of the time-kill data, based on the sigmoidal Emax equation, generated parameters for three levels of efficacy, namely bacteriostatic, bactericidal (3log10 reduction) and 4log10 reduction in bacterial counts. For these levels, mean AUC(0-24 h) /MIC serum values for M. haemolytica were 29.1, 57.3 and 71.5 h, respectively, and corresponding values for P. multocida were 28.1, 44.9 and 59.5 h. Amoxicillin PK was determined in calf serum, inflamed (exudate) and noninflamed (transudate) tissue cage fluids, after intramuscular administration of a depot formulation at a dosage of 15 mg/kg. Mean residence times were 16.5 (serum), 29.6 (exudate) and 29.0 h (transudate). Based on serum MICs, integration of in vivo PK and in vitro PD data established maximum concentration (Cmax )/MIC ratios of 13.9:1 and 25.2:1, area under concentration-time curve (AUC0-∞ )/MIC ratios of 179 and 325 h and T>MIC of 40.3 and 57.6 h for P. multocida and M. haemolytica, respectively. Monte Carlo simulations for a 90% target attainment rate predicted single dose to achieve bacteriostatic and bactericidal actions over 48 h of 17.7 and 28.3 mg/kg (M. haemolytica) and 17.7 and 34.9 mg/kg (P. multocida).
Asunto(s)
Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Enfermedades de los Bovinos/tratamiento farmacológico , Mannheimia haemolytica/efectos de los fármacos , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/efectos de los fármacos , Neumonía Enzoótica de los Becerros/tratamiento farmacológico , Amoxicilina/administración & dosificación , Amoxicilina/farmacocinética , Animales , Animales Recién Nacidos , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Bovinos , Enfermedades de los Bovinos/microbiología , Preparaciones de Acción Retardada , Femenino , Inyecciones Intramusculares/veterinaria , Pruebas de Sensibilidad Microbiana/veterinaria , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/microbiología , Neumonía Enzoótica de los Becerros/microbiologíaRESUMEN
BACKGROUND: Pasteurella multocida causes numerous economically relevant diseases in livestock including rabbits. Immunisation is only variably effective. Prophylactic antibiotics are used in some species but are contra-indicated in rabbits, due to their adverse effects on the rabbit microbiota. There is therefore a substantial need for alternative forms of infection control in rabbits; we investigated the effect of oral ß-glucan on P. multocida infection in this species. RESULTS: Thirthy-five New Zealand White rabbits were randomly divided into five groups of seven animals. Three groups were inoculated with Pasteurella multocida intranasally (in.), a physiologically appropriate challenge which reproduces naturally acquired infection, and received either (1-3), (1-6) ß-glucans or placebo. Four other groups were inoculated both in. and intramuscularly (im.), representing a supra-physiological challenge, and received either (1-3), (1-6) ß-glucans, antibiotic or placebo. ß-glucans given prophylactically were highly effective in protecting against physiological (in.) bacterial challenge. They were less effective in protecting against supra-physiological bacterial challenge (in. and im.), although they extended survival times. This latter finding has practical relevance to breeders as it extends the window in which heavily infected and symptomatic animals can be salvaged with antibiotics. CONCLUSIONS: In our study, (1-3), (1-6) ß-glucans were highly effective in protecting against a model of naturally acquired P. multocida infection and extended survival times in the supra-physiological model. Enrofloxacin was effective in protecting against supra-physiological infection. We are currently reviewing the use of combined prophylaxis.
Asunto(s)
Glucanos/uso terapéutico , Infecciones por Pasteurella/veterinaria , Pasteurella multocida , Conejos/microbiología , beta-Glucanos/uso terapéutico , Animales , Antibacterianos/uso terapéutico , Suplementos Dietéticos , Enrofloxacina , Femenino , Fluoroquinolonas/uso terapéutico , Masculino , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/prevención & control , Pasteurella multocida/efectos de los fármacosRESUMEN
Pasteurella multocida is a leading cause of fowl cholera in both free-range pasture and conventional/commercially raised poultry. Its infection is a serious threat to poultry health and overall flock viability. Organic poultry is comparatively more vulnerable to this pathogen. It is a significant cause of production loss and price increase of poultry products, specifically organic poultry products. Some plant products are well documented as sources of natural antimicrobials such as polyphenols found in different berry pomaces and citrus oil. Pomace, a byproduct (primarily of seeds and skins) of fruits used for juice and wine production, and citrus oil, the byproduct of citrus juice production, show promising antimicrobial activity against various pathogens. Here, we showed for the first time that blackberry and blueberry pomace extracts and citrus oil inhibited P. multocida growth. Minimum bactericidal concentrations were determined as 0.3 and 0.4 mg/mL gallic acid equivalent for blackberry and blueberry pomace extracts, respectively. Similarly, only 0.05% citrus oil (vol/vol) completely inhibited P. multocida growth. Under shaking conditions, the antimicrobial activity of both pomace extracts and citrus oil was more intensive. Even citrus oil vapor also significantly reduced the growth of P. multocida. In addition, cell surface hydrophobicity of P. multocida was increased by 2- to 3-fold and its adherence to chicken fibroblast (DF1) and bovine mammary gland (MacT) cells was reduced significantly in the presence of pomace extracts only. This study indicates that these natural products might be good alternatives to conventional antimicrobial agents, and hence, may be used as feed or water supplements to control fowl cholera and reduce production loss caused by P. multocida.
Asunto(s)
Antiinfecciosos/farmacología , Pollos , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/efectos de los fármacos , Extractos Vegetales/farmacología , Aceites de Plantas/farmacología , Enfermedades de las Aves de Corral/tratamiento farmacológico , Animales , Arándanos Azules (Planta)/química , Bovinos , Citrus/química , Frutas/química , Pruebas de Sensibilidad Microbiana/veterinaria , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/microbiología , Pasteurella multocida/crecimiento & desarrollo , Enfermedades de las Aves de Corral/microbiología , Rosaceae/químicaRESUMEN
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis. Recently, rifaximin, a non-absorbable antibiotic which is used to prevent recurrent hepatic encephalopathy, has been proposed as effective prophylaxis for SBP. Here, we present an unusual case of SBP under treatment with rifaximin. A 50-year-old woman with liver cirrhosis was admitted because of tense ascites and abdominal pain. She was under long-term oral prophylaxis with rifaximin due to hepatic encephalopathy. Paracentesis revealed SBP caused by Pasteurella multocida, which was sensitive to multiple antibiotics, including rifaximin. Treatment with ceftriaxone resulted in rapid resolution of the peritonitis and restoration of the patient. Since P. multocida is usually transmitted from pets, the patient's cat was tested and could be identified as the most likely source of infection. This case should elicit our awareness that uncommon pathogens and unusual routes of transmission may lead to SBP, despite antibacterial prophylaxis with non-absorbable antibiotics. Nevertheless, such infections may still remain sensitive to systemic therapy with conventional antibiotics.
Asunto(s)
Antiinfecciosos/uso terapéutico , Profilaxis Antibiótica/métodos , Cirrosis Hepática/complicaciones , Infecciones por Pasteurella/diagnóstico , Pasteurella multocida/aislamiento & purificación , Peritonitis/diagnóstico , Rifamicinas/uso terapéutico , Ceftriaxona/uso terapéutico , Femenino , Humanos , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones por Pasteurella/microbiología , Infecciones por Pasteurella/patología , Infecciones por Pasteurella/prevención & control , Pasteurella multocida/efectos de los fármacos , Peritonitis/microbiología , Peritonitis/patología , Peritonitis/prevención & control , Rifaximina , Resultado del TratamientoRESUMEN
Florfenicol was administered subcutaneously to 10 calves at a dose of 40 mg/kg. Pharmacokinetic-pharmacodynamic (PK-PD) integration and modelling of the data were undertaken using a tissue cage model, which allowed comparison of microbial growth inhibition profiles in three fluids, serum, exudate and transudate. Terminal half-lives were relatively long, so that florfenicol concentrations were well maintained in all three fluids. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration were determined in vitro for six strains each of the calf pneumonia pathogens, Mannhemia haemolytica and Pasteurella multocida. An PK-PD integration for three serum indices provided mean values for P. multocida and M. haemolytica, respectively, of 12.6 and 10.4 for Cmax /MIC, 183 and 152 h for AUC0-24 h /MIC and 78 and 76 h for T>MIC. Average florfenicol concentrations in serum exceeded 4 × MIC and 1.5 × MIC for the periods 0-24 and 48-72 h, respectively. Ex vivo growth inhibition curves for M. haemolytica and P. multocida demonstrated a rapid (with 8 h of exposure) and marked (6 log10 reduction in bacterial count or greater) killing response, suggesting a concentration-dependent killing action. During 24-h incubation periods, inhibition of growth to a bacteriostatic level or greater was maintained in serum samples collected up to 96 h and in transudate and exudate samples harvested up to 120 h. Based on the sigmoidal Emax relationship, PK-PD modelling of the ex vivo time-kill data provided AUC0-24 h /MIC serum values for three levels of growth inhibition, bacteriostatic, bactericidal and 4 log10 decrease in bacterial count; mean values were, respectively, 8.2, 26.6 and 39.0 h for M. haemolytica and 7.6, 18.1 and 25.0 h for P. multocida. Similar values were obtained for transudate and exudate. Based on pharmacokinetic and PK-PD modelled data obtained in this study and scientific literature values for MIC distributions, Monte Carlo simulations over 100 000 trials were undertaken to predict once daily dosages of florfenicol required to provide 50% and 90% target attainment rates for three levels of growth inhibition, namely, bacteriostasis, bactericidal action and 4 log10 reduction in bacterial count.
Asunto(s)
Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Bovinos/metabolismo , Tianfenicol/análogos & derivados , Animales , Antibacterianos/administración & dosificación , Antibacterianos/química , Área Bajo la Curva , Bovinos/sangre , Exudados y Transudados/química , Femenino , Semivida , Inyecciones Subcutáneas , Mannheimia haemolytica/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , Pasteurella multocida/efectos de los fármacos , Tianfenicol/administración & dosificación , Tianfenicol/química , Tianfenicol/farmacocinética , Tianfenicol/uso terapéuticoRESUMEN
BACKGROUND: Sheep constitute the second major component of livestock in Ethiopia. However, efficient utilization of this potential resource is hampered by combination of health problems, poor management and feed shortage. Haramaya district is one of the remote settings in Ethiopia where information about the livestock disease is not well documented. Hence this study was conducted to determine the causative agents and their antimicrobial susceptibility pattern of bacterial Pasteurella isolates among pneumonic ovine in Haramaya district, Eastern Hararghe, Ethiopia. RESULTS: Out of 256 samples examined, Pasteurella was isolated in 64 (25%), of which 38 (59.4%) were from lungs and 26 (40.6%) were from nasal cavities. 87.5% of the isolates were Mannheimia haemolytica and 12.5% were Pasteurella multocida. All of the isolates from the lungs were Mannheimia haemolytica whereas 69% of the isolates from nasals cavities were Mannheimia haemolytica. Age and body temperature were significantly associated with Pasteurella isolates from clinic (P < 0.05). Despite diverse in the site of origins, the isolates exhibited uniformity in sensitivity to a majority of the antibacterial agents. The most effective drug was Cholramphenicol (100%) followed by Sulfamethoxazole (89.1%) and Tetracycline (84.4%). Both species were completely resistant to Gentamycin and Vancomycin. CONCLUSION: Mannheimia haemolytica is the most common cause of ovine pneumonic pasteurellosis in the study area. The isolates were susceptible to limited antimicrobial agents. Therefore, the antimicrobial susceptibility test should be conducted before treatment, except for critical cases.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Pasteurella/veterinaria , Pasteurella/efectos de los fármacos , Enfermedades de las Ovejas/microbiología , Animales , Estudios Transversales , Etiopía/epidemiología , Femenino , Pulmón/microbiología , Masculino , Mannheimia haemolytica/efectos de los fármacos , Mannheimia haemolytica/aislamiento & purificación , Pruebas de Sensibilidad Microbiana/veterinaria , Cavidad Nasal/microbiología , Pasteurella/aislamiento & purificación , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/epidemiología , Infecciones por Pasteurella/microbiología , Pasteurella multocida/efectos de los fármacos , Pasteurella multocida/aislamiento & purificación , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Neumonía Bacteriana/veterinaria , Ovinos , Enfermedades de las Ovejas/tratamiento farmacológicoRESUMEN
This study validated the use of mutant prevention concentration (MPC) and pharmacokinetic and pharmacodynamic (PK-PD) modeling approach for optimization of dose regimen of enrofloxacin to contain the emergence of Pasteurella multocida resistance. The PK and PD characteristics of enrofloxacin were investigated in buffalo calves after intramuscular administration at a dose rate of 12 mg/kg. The concentration of enrofloxacin and ciprofloxacin in serum were determined by high-performance liquid chromatography. The serum peak concentration (Cmax), terminal half-life (t1/2K10), volume of distribution (Vd(area)/F) and mean residence time (MRT) of enrofloxacin were 1.89 ± 0.35 µg/ml, 5.14 ± 0.66 h, 5.59 ± 0.99 l/kg/h and 8.52 ± 1.29 h, respectively. The percent metabolite conversion ratio of ciprofloxacin to enrofloxacin was 79. The binding of enrofloxacin to plasma proteins was 11%. The MIC, MBC and MPC for enrofloxacin against P. multocida were 0.05, 0.06 µg/ml and 1.50 µg/ml.In vitro and ex-vivo bactericidal activity of enrofloxacin was concentration dependent. Modeling of ex-vivo growth inhibition data to the sigmoid Emax equation provided AUC24h/MIC values to produce bacteriostatic (19 h), bactericidal (43 h) and bacterial eradication (64 h). PK-PD data in conjunction with MPC and MIC90 data predicted dosage schedules for enrofloxacin that may achieve optimum efficacy in respect of bacteriological and clinical cure and minimize the risk of emergence of resistance.
Asunto(s)
Antibióticos Antineoplásicos/uso terapéutico , Búfalos/microbiología , Fluoroquinolonas/uso terapéutico , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/efectos de los fármacos , Animales , Animales Recién Nacidos , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/farmacocinética , Ciprofloxacina/administración & dosificación , Ciprofloxacina/farmacocinética , Ciprofloxacina/uso terapéutico , Farmacorresistencia Bacteriana , Enrofloxacina , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/farmacocinética , Inyecciones Intramusculares/veterinaria , Masculino , Pruebas de Sensibilidad Microbiana/veterinaria , Infecciones por Pasteurella/tratamiento farmacológico , Infecciones por Pasteurella/microbiologíaRESUMEN
BACKGROUND: Inadequate localized drug concentrations and systemic adverse effects are among the concerns when regional infections are treated with systemic antibiotics. We designed and fabricated a poly(D,L)-lactide-co-glycolide (PLGA)-based biodegradable drug delivery system and evaluated the release of antibiotics both in vitro and in vivo. METHODS: PLGA copolymer and penicillin G sodium were mixed, compressed, and sintered to fabricate biodegradable antibiotic beads. The beads were placed in phosphate-buffered saline to test the characteristics of in vitro drug release. The beads then were introduced into the pleural cavities through chest tubes of six New Zealand white rabbits. Daily pleural effusion was collected to measure the antibiotic concentration and bacterial inhibitory characteristics. RESULTS: Forty percent of the penicillin was released in the first day in the in vitro study. The rest of the antibiotic was then gradually released in the following 30 days. All six animals survived the experiment. The initial surge of drug release was less significant in the pleural cavity than in the phosphate-buffered saline. The drug concentrations were well above the minimum inhibitory concentration breakpoint for penicillin susceptibility throughout the study period in both in vitro (30 days) and in vivo (14 days) studies. CONCLUSIONS: These preliminary findings demonstrated that the biodegradable PLGA antibiotic beads could achieve a fairly steady antibiotic release in the pleural cavity for at least 2 weeks. This drug delivery system may have the potential to serve as an adjuvant treatment of pleural cavity infection.
Asunto(s)
Implantes Absorbibles , Antibacterianos/farmacocinética , Bombas de Infusión Implantables , Ácido Láctico , Pasteurella multocida/efectos de los fármacos , Penicilina G/farmacocinética , Cavidad Pleural/efectos de los fármacos , Cavidad Pleural/metabolismo , Ácido Poliglicólico , Animales , Disponibilidad Biológica , Tubos Torácicos , Cromatografía Líquida de Alta Presión , Pruebas Antimicrobianas de Difusión por Disco , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Microesferas , Cavidad Pleural/microbiología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , ConejosRESUMEN
OBJECTIVE: To determine associations between in vitro minimum inhibitory concentrations (MICs) of tilmicosin against Mannheimia haemolytica and Pasteurella multocida and in vivo tilmicosin treatment outcome among calves with clinical signs of bovine respiratory disease (BRD). DESIGN: Observational, retrospective, cohort study. ANIMALS: 976 feeder calves with clinical signs of BRD enrolled in 16 randomized clinical trials. PROCEDURES: Records of clinical trials from October 26, 1996, to November 15, 2004, were searched to identify calves with BRD from which a single isolate of M haemolytica or P multocida was identified via culture of deep nasal swab samples prior to treatment with tilmicosin (10 mg/kg [4.5 mg/lb], SC) and for which MICs of tilmicosin against the isolate were determined. The MICs of tilmicosin against recovered isolates and response to tilmicosin treatment were evaluated. RESULTS: Tilmicosin resistance among M haemolytica and P multocida isolates was uncommon (6/745 [0.8%] and 16/231 [6.9%], respectively). Treatment outcome, defined as success or failure after tilmicosin treatment, did not vary with the MIC of tilmicosin against recovered isolates. The proportion of treatment failures attributed to M haemolytica isolates categorized as resistant (MIC of tilmicosin, ≥ 32 µg/mL) or not susceptible (MIC of tilmicosin, ≥ 16 µg/mL), was 0.2% and 0.5%, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: Recovery of tilmicosin-resistant M haemolytica or P multocida isolates was rare, and no association was detected between MIC of tilmicosin and treatment response.